Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026

Same author

Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.

Pain and therapy·2026

Same author

Focus on migraine prodrome: what should clinicians know?

Current opinion in neurology·2026

Same author

Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.

Cephalalgia : an international journal of headache·2026

Same author

Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed.

European journal of neurology·2026

Same author

The optimisation of migraine prevention: an urgent need.

The Lancet. Neurology·2026

Same journal

Update on Genetic Chorea.

Current neurology and neuroscience reports·2026

Same journal

Gastrointestinal Dysfunction in Critically Ill Patients With Traumatic Brain Injury: Clinical Implications and Putative Mechanisms: a Narrative Review.

Current neurology and neuroscience reports·2026

Same journal

The Potential of Rehabilitation to Amplify Experience-Induced Myelin Plasticity and Remyelination in Multiple Sclerosis: A Narrative Review.

Current neurology and neuroscience reports·2026

Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026

Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026

Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 20, 2025

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

CGRP Modulating Therapies: An Update.

Kate Bedrin^1,2, Tulsi Shah³, Shivani Vaidya³

¹Virginia Mason Franciscan Health, Seattle, USA. Kate.Bedrin@commonspirit.org.

Current Neurology and Neuroscience Reports

|July 17, 2024

Summary

This summary is machine-generated.

Calcitonin-gene related peptide (CGRP) therapies offer a safe and well-tolerated approach to migraine management. These migraine-specific treatments represent a significant advancement in addressing the pathophysiology of this neurological condition.

Keywords:

Calcitonin gene-related peptide Calcitonin gene-related peptide monoclonal antibody Calcitonin gene-related peptide receptor antagonist Migraine treatment Migraine without aura

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

Related Experiment Videos

Last Updated: Jun 20, 2025

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

Area of Science:

Neurology
Pharmacology

Background:

Calcitonin-gene related peptide (CGRP) is a key neuropeptide implicated in the pathophysiology of migraine.
CGRP plays a crucial role in the vascular changes associated with migraine attacks.

Purpose of the Study:

To summarize the most clinically relevant literature on CGRP modulating therapies for migraine.
To provide an overview of the current landscape of CGRP-targeted treatments.

Main Methods:

Literature review focusing on clinically relevant articles.
Selection of studies based on author expertise and clinical significance.

Main Results:

CGRP modulating therapies are a novel and effective treatment option for migraine.
These therapies demonstrate favorable safety and tolerability profiles.

Conclusions:

CGRP modulating therapies are a valuable addition to the migraine treatment armamentarium.
Their migraine-specific action and tolerability distinguish them from traditional treatments.
Ongoing research and real-world data will further elucidate the long-term benefits and applications of CGRP therapies in migraine management.